Skip to main content
Shunrong Ji on Muck Rack

Shunrong Ji

As seen in: Color Research & Application, Nature, ScienceDirect, BMC Cancer, Molecular Cancer, Cell Press, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shunrong

Contact Shunrong, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors - Cell Death & Disease

|
By Xiaowu Xu, Xianjun Yu, Shunrong Ji
| Nature Verified
Abstract Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells, which has not been fully elucidated.
Open in Who Shared Issue with article?

Proteogenomic Characterization of Non-Functional Pancreatic Neuroendocrine Tumors Unravels Clinically Relevant Subgroups

|
By Shunrong Ji
| Texas Medical Center
10.1016/j.ccell.2025.03.016 Pancreatic Neoplasms, Humans, Proteogenomics, Animals, Mice, Neuroendocrine Tumors, Mice, Knockout, Tumor Microenvironment, Female, Male, Proteomics, Prognosis, Proto-Oncogene Proteins yes Ji, Shunrong; Cao, Lihua; Gao, Jing; et al., "Proteogenomic Characterization of Non-Functional Pancreatic Neuroendocrine Tumors Unravels Clinically Relevant Subgroups" (2025). Faculty and Staff Publications. 5124. https://digitalcommons.library.tmc.edu/baylor_docs/5124
Open in Who Shared Issue with article?

Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts

|
By Shunrong Ji, Xianjun Yu, Steve Mao Verified, Nastaran Fazel Modares
| ScienceDirect Verified
Therapeutic advances in immune checkpoint blockade (ICB) therapies have significantly improved cancer immunotherapy, particularly for solid tumors.
Open in Who Shared Issue with article?
See all 8 articles